Polymer particles

US12364786B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12364786-B2
Application numberUS-202318230569-A
CountryUS
Kind codeB2
Filing dateAug 4, 2023
Priority dateSep 28, 2016
Publication dateJul 22, 2025
Grant dateJul 22, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

First claim

Opening claim text (preview).

We claim: 1. A polymer particle, comprising: a reaction product of a prepolymer solution including a solvent, at least one monomer, and at least one crosslinker having a structure: wherein m is 0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, and n is 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18; wherein p is 0, 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; wherein q is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, and r is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; wherein s is 0, 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; wherein t is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, and u is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; wherein v is 0, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; or wherein w is 0, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 2. The polymer particle of claim 1 having a diameter between about 40 μm and about 1,200 μm. 3. The polymer particle of claim 1 having a diameter between about 75 μm and about 1,200 μm. 4. The polymer particle of claim 1 , wherein the at least one monomer includes at least one functional group. 5. The polymer particle of claim 4 , wherein the at least one functional group is acrylate, acrylamide, methacrylate, or methacrylamide. 6. The polymer particle of claim 1 , wherein the at least one monomer includes an ionizable functional group. 7. The polymer particle of claim 1 , wherein the prepolymer solution further includes a second crosslinker including a second linkage selected from an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, and a peptide cleavable by matrix cathepsins. 8. The polymer particle of claim 1 , wherein the polymer particles are biodegradable. 9. The polymer particle of claim 1 , wherein the polymer particles are biostable. 10. The polymer particle of claim 1 , wherein the at least one monomer is dimethylacrylamide. 11. The polymer particle of claim 1 , wherein the at least one monomer is acrylamide. 12. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein m is 0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, and n is 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18. 13. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein p is 0, 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 14. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein q is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, and r is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 15. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein s is 0, 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 16. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein t is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, and u is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 17. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein v is 0, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 18. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein w is 0, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 19. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein v is 1. 20. The polymer particle of claim 1 , wherein the at least one crosslinker has a structure wherein p is 1.

Assignees

Inventors

Classifications

  • unconjugated · CPC title

  • Materials at least partially resorbable by the body · CPC title

  • obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence) · CPC title

  • Acrylamide; Methacrylamide · CPC title

  • for embolization or occlusion, e.g. vaso-occlusive compositions or devices · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12364786B2 cover?
Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.
Who is the assignee on this patent?
Terumo Corp
What technology area does this patent fall under?
Primary CPC classification A61L24/06. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).